Metabolic Syndrome Array II Quality Control
Metabolic Syndrome Array II Quality Control
A multi-analyte quality control with target values and ranges provided for 3 parameters associated with metabolic syndrome.
Features & Benefits
- Lyophilised for enhanced stability
- 100% human material
- Stable to expiry date at 2oC – 8oC
- Reconstituted stability of 72 hours at 2oC – 8oC and 7 days at -20°C
- Assayed values available for Randox Biochip systems
| Description | Size | Analytes | Cat No | |
|---|---|---|---|---|
| Metabolic Syndrome Array II Control | 3 x 3 x 1ml | 3 | EV3761 | |
| Metabolic Syndrome Array II Calibrator | 9 x 1 ml | 3 | EV3760 |
Analytes
- Adiponectin
- CRP
- Cystatin C
Transplant Associated Diseases | Qnostics Molecular Controls
Transplant Associated Diseases | Qnostics Molecular Controls
Advances in transplant medicine have greatly improved the prospects of transplant recipients. However, pathogen infection and in particular, viral reactivation remain significant contributors to transplant patient morbidity and mortality.
Qnostics’ Q Control and Analytical Q Panel ranges cover a number of viruses and fungal pathogens of particular concern, including: HSV, CMV, EBV, ADV, JCV and BKV, with Molecular Q Panels covering HSV, HHV6, CMV, EBV, ADV, JCV and BKV.
Q Controls
Qnostics’ ‘Q’ Controls are positive run controls intended to help laboratories monitor their molecular diagnostic assay on a run-to-run basis within customer derived limits. These third-party independent external controls will ensure that assay drift is detected, monitored and managed allowing the laboratory to continue to provide accurate and reliable results. They also help support a laboratory’s regulatory requirements under the standard ISO 15189.
Adenovirus (ADV) Control
Pathogen – Adenovirus (ADV)
Genotype – Type 1
Matrix – Transport Medium
Stability – Single use control designed to be used immediately minimising the risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
ADV Molecular Q Control
Product code: ADVMQC | Pack size: 5×1 ml
BK Virus (BKV) Control
Pathogen – BK Virus (BKV)
Genotype – Type 1b-2
Matrix – Plasma
Stability – Single use control designed to be used immediately minimising the risk of contamination
Shelf life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
BKV Molecular Q Control
Product code: BKVMQC | Pack size: 5×1 ml
Cytomegalovirus (CMV) Control
Pathogen – Cytomegalovirus (CMV)
Genotype – AD169
Matrix – Plasma
Stability – Single use control designed to be used immediately minimising the risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
CMV Medium Q Control
Product code: CMVMQC | Pack size: 5×1 ml
Epstein-Barr Virus (EBV) Control
Pathogen – Epstein-Barr Virus (EBV)
Genotype – B-95
Matrix – Plasma
Stability – Single use control designed to be used immediately minimising the risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
EBV Molecular Q Control
Product code: EBVMQC | Pack size: 5×1 ml
JC Virus (JCV) Control
Pathogen – JC Virus (JCV)
Genotype – Type 1A
Matrix – Plasma
Stability – Single use control designed to be used immediately minimising the risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
JCV Medium Q Control
Product code: JCVMQC | Pack size: 5×1 ml
Molecular Q Panels
Molecular Q Panels consist of four individual levels, including a negative, and are intended to evaluate the assays’ clinical range. Molecular Q Panels can also be used to support laboratory training and in the assessment and development of molecular diagnostic assays from extraction phase through amplification and finally detection.
Adenovirus (ADV) Molecular Q Panel
Pathogen – Adenovirus (ADV)
Genotype – Type 1
Matrix – Viral Transport Medium
Stability – Single use Q-Panel designed to be used immediately minimising risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
ADV Molecular Q Panel
Product code: ADVMQP | Pack size: 4×1 ml
BK Virus (BKV) Molecular Q Panel
Pathogen – BK Virus (BKV)
Genotype – Type 1b-2
Matrix – Plasma
Stability – Single use Q-Panel designed to be used immediately minimising the risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
BKV Molecular Q Panel
Product code: BKVMQP | Pack size: 4×1 ml
Cytomegalovirus (CMV) Molecular Q Panel
Pathogen – Cytomegalovirus (CMV)
Genotype – AD169
Matrix – Plasma
Stability – Single use Q-Panel designed to be used immediately minimising risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
CMV Molecular Q Panel
Product code: CMVMQP | Pack size: 4×1 ml
Epstein-Barr Virus (EBV) Molecular Q Panel
Pathogen – Epstein-Barr Virus (EBV)
Genotype – B-95
Matrix – Plasma
Stability – Single use Q-Panel designed to be used immediately minimising risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
EBV Molecular Q Panel
Product code: EBVMQP | Pack size: 4×1 ml
Human Herpes Virus 6 (HHV6) Molecular Q Panel
Pathogen – Human Herpes Virus 6 (HHV6)
Genotype – Type A-GS
Matrix – Plasma
Stability – Single use Q-Panel designed to be used immediately minimising risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status -RUO
__________
HHV6 Molecular Q Panel
Product code: HHV6MQP | Pack size: 4×1 ml
JC Virus (JCV) Molecular Q Panel
Pathogen – JC Virus (JCV)
Genotype – Type 1A
Matrix – Plasma
Stability – Single use Q-Panel designed to be used immediately minimising risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
JCV Molecular Q Panel
Product code: JCVMQP | Pack size: 4×1 ml
Analytical Q Panels
Analytical ‘Q’ Panels are designed to cover the dynamic range of an assay allowing the laboratory to assess the linearity, LOD and LOQ of their assay. Each panel contains a dilution series covering the analytical range of most assays, in a linear progression, all of which should be treated as a patient sample within an assay run.
Adenovirus (ADV) Analytical Q Panel
Pathogen – Adenovirus (ADV)
Genotype – Type 1
Matrix – Viral Transport Medium
Number of Levels – 8
Stability – Single use Q-Panel designed to be used immediately minimising the risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
ADV Analytical Q Panel
Product code: ADVAQP | Pack size: 8×1 ml
BK Virus (BKV) Analytical Q Panel
Pathogen – BK Virus (BKV)
Genotype – Type 1b-2
Matrix – Plasma
Number of Levels – 10
Stability – Single use Q-Panel designed to be used immediately minimising the risk of contamination
Shelf life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
BKV Analytical Q Panel
Product code: BKVAQP | Pack size: 10×1 ml
Cytomegalovirus (CMV) Analytical Q Panel
Pathogen – Cytomegalovirus (CMV)
Genotype – AD169
Matrix – Plasma
Number of Levels – 9
Stability – Single use Q-Panel designed to be used immediately minimising the risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
__________
CMV Analytical Q Panel
Product code: CMVAQP | Pack size: 9×1 ml
Epstein-Barr Virus (EBV) Analytical Q Panel
Pathogen – Epstein-Barr Virus (EBV)
Genotype – B-95
Matrix – Plasma
Number of Levels – 10
Stability – Single use Q-Panel designed to be used immediately minimising risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – CE & RUO
EBV Analytical Q Panel
Product code: EBVAQP | Pack size: 10×1 ml
Human Herpes Virus 6 (HHV6) Analytical Q Panel
Pathogen – Human Herpes Virus 6 (HHV6)
Genotype – Type A-GS
Matrix – Plasma
Number of Levels – 10
Stability – Single use Q Panel designed to be used immediately minimising risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – RUO
__________
Human Herpes Virus 6 (HHV6) Analytical Q Panel
Product code: HHV6AQP | Pack size: 10×1 ml
JC Virus (JCV) Analytical Q Panel
Pathogen – JC Virus (JCV)
Genotype – Type 1A
Matrix – Plasma
Number of Levels – 10
Stability – Single use Q Panel designed to be used immediately minimising risk of contamination
Shelf Life – Up to 2 years after date of manufacture
Regulatory Status – RUO
__________
JCV Analytical Q Panel
Product code: JCVAQP | Pack size: 10×1 ml
Want to know more?
Contact us or visit our Qnostics page to learn more.
Related Products
Molecular EQA
Acusera Controls
RIQAS EQA
Resource Hub
Nutritional status: copper deficiency
Did you know that copper is an essential trace mineral present in all tissues? It works with iron to help the body form red blood cells. It also helps keep the blood vessels, nerves, immune system and bones healthy while also aiding in iron absorption. In rare situations, copper deficiency can occur and lead to anaemia and osteoporosis.
Symptoms of copper deficiency include:
- Fatigue & weakness as cells use copper to generate ATP, the body’s main source of energy. This means that copper deficiency could affect your energy levels.
- Frequent sickness as copper plays an important role in maintaining a healthy immune system.
- Weak and brittle bones as copper is involved in the processes that create cross-links inside your bones. These cross-links ensure bones are healthy and strong.
- Problems with memory and learning as copper plays an important role in brain function and development.
Sensitivity to cold as copper, along with minerals like zinc, help maintain optimal thyroid gland function. Low thyroid levels can make you feel colder more easily.
There are many foods that are high in copper. These include leafy greens, including turnip, greens, spinach, kale and mustard greens. Asparagus and summer squash are two other excellent sources of copper while legumes, whole grains, nuts and seeds are also good sources of the substance.
Randox Reagents, RX and QC are helping to diagnose copper deficiency at the earliest possible stage. The Randox copper assay is used to measure the levels of copper in the blood in order to determine copper toxicity. Combining this with the Randox zinc assay can aid in identifying the cause of liver damage in a patient, leading to correct treatment and recovery.
Find out more about how Randox is helping to diagnose nutritional status and deficiencies here: https://www.randox.com/nutritional-status/
How Randox is helping to diagnose nutritional status
At Randox, we’re dedicated to improving health worldwide and are consistently trying to break our own innovative records. Throughout the month of July, we’ll be introducing you to how we’re helping to diagnose nutritional deficiencies and define individual nutritional status among patients.
Zinc
Randox Reagents
Randox Reagents have the highest quality reagents on the market and a test menu comprising of over 113 assays. Unique to Randox is the zinc assay which is important in the diagnosis of kidney and liver damage.
Our zinc assay can be used to measure the levels of zinc in a patient’s urine providing insight into the levels of zinc in the body. This, combined with our copper assay, can aid in identifying the cause of liver damage in a patient, leading to correct treatment and recovery.
The RX series
The RX series offers the most comprehensive testing profile for assessing nutritional status to identify any nutritional deficiencies or any other nutritional issues within an individual.
The RX series zinc test can identify a zinc deficiency in an individual which is often a result of a low dietary intake and can lead to many problems including impaired immune and cognitive functions, kidney disease and diabetes.
Randox Quality Control
World-leading diagnostics would be nothing without world-leading quality control materials to ensure consistency and accuracy across all results. The Randox Acusera Liquid Chemistry Premium Plus control is the most comprehensive chemistry control available.
Stay tuned over the course of the month as we highlight how we’re helping in the fight against nutrient deficiencies.
Randox QC International Resource Hub
Designed to improve the quality of Point of Care Testing (POCT) in locations such as pharmacies, GP surgeries, hospital out patient departments, sports clinics, supermarkets, diagnostic/treatment and walk-in centres.
RIQAS Point of Care EQA provides independent evidence of the accuracy and reliability of test results.
RX series (Concept 3)
The RX series range of clinical chemistry analysers includes both semi-automated and fully automated testing for a range of clinical settings. With a world leading test menu comprising of routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants and diabetes testing, the RX series offers laboratories the complete clinical chemistry package and results you can trust. The RX series was built with three core values in mind – Reliability, Accuracy and Precision.
Consolidation of Routine & Specialised Testing on One Single Platform
With an extensive product portfolio covering over 100 disease markers within routine and nice testing, the RX series removes the need for a separate nephelometry system for specific proteins and allows laboratories to bring all testing in-house; thus ensuring minimal downtime and providing real cost savings through consolidation.
Low Reagents & Sample Volumes
Built with excellence in mind, the RX series range of analsyers require a low sample volume to deliver consistent high quality results which is beneficial when working with paediatric patients and animals. Combined with our high quality reagents, the RX series reduce the possibility of misdiagnoses, offering accurate, reliable and precise results each time, every time.
Unrivalled Customer Support
Our team of trained engineers are on hand to work with you in preserving the continuity of your operations while maximising the potential of your RX series instrument. We know time is critical in any laboratory and our global network means we are uniquely positioned to meet your needs with local service and support whenever you need it.
Fully Automated
Test Menu
Semi-Automated
Test Menu
Niche
Test Menu
QCMD – Molecular External Quality Control
QCMD is a world leading External Quality Assessment (EQA) / Proficiency Testing (PT) scheme, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases.
With an extensive database of over 15,000 participants in over 120 countries, QCMD is one of the largest providers of molecular EQA in the field of molecular diagnostics.
Blood Borne Viruses
Central Nervous System Diseases
Drug Resistance
Exotic / Emerging Diseases
Gastrointestinal Diseases
Immunocompromised Associated Diseases
Multiple Pathogen / Syndromic Infections
Respiratory Diseases
Serology
Sexually Transmitted Infections
Transplant Associated diseases
Typing
New Pilot Studies
After the close of the results return phase, EQA participants will receive an individual report outlining their performance relative to their method and technology groups. A supplementary report may be commissioned – this includes any additional relevant information regarding the annual EQA distribution, as well as scientific expert commentary and feedback on the overall results within that distribution.
*Randox are authorised by QCMD to provide the QCMD EQA schemes under a strategic global partnership. The EQA design, composition, data analysis & reporting remain the responsibility of QCMD. Please refer to specific geographical regions for further details on availability.
Explore Further
Contact Us
QCMD Website
RIQAS EQA
Protected: RX series (Concept)
Ā£50m Randox Centres of Excellence launched in Northern Ireland
A record £50 million investment which will deliver cutting-edge technologies to diagnose conditions like cancer, heart conditions and infectious diseases has been announced by Northern Ireland diagnostics company Randox Laboratories and Invest Northern Ireland.
This major project involves the establishment of three Centres of Excellence, enabling Randox R&D scientists to work collaboratively with colleagues from Queen’s University Belfast and Ulster University. The centres are being officially launched today at the Randox Science Park. The ceremony will include a keynote address from Sir John Bell, who chaired the UK Government’s Life Sciences Industrial Strategy Board.
Advanced diagnostics have been identified as key to delivering sustainable improvement to healthcare systems struggling to cope with increasing levels of chronic and preventable conditions. Having been focused in this field for over 36 years, Randox has a successful track record of developing new and innovative tests – examples include assessing those at risk of Alzheimer’s disease and genetic cardiac conditions, to promote and enable preventive treatment, and a new clinically-approved test to diagnose prediabetes.
Managing Director of Randox Laboratories, Dr Peter FitzGerald, who today launched the three Centres of Excellence, said;
“When almost a quarter of the deaths of people under 75 in the UK are considered preventable, we need to ask ourselves what can be done to improve healthcare outcomes. There is an undeniable case for radical change in the way healthcare is delivered, and sophisticated diagnostics will be at the fore of this revolution.
“Enabling earlier and more accurate diagnosis, to identify those at the earliest stages of illness, ideally before the onset of any symptoms, is a game-changer. Through early intervention we can restrict the development of chronic conditions and improve people’s lives. Our view of the future is one where people are empowered through earlier diagnosis to stay healthier for longer, and where healthcare systems are freed to deliver quality services to patients. Our announcement today demonstrates our continuing commitment in this field.
“We are grateful for the support offered by Invest NI and look forward to addressing these pressing healthcare needs.”
The Centres of Excellence will focus respectively on clinical diagnostics, engineering for biosciences and quality control. The project, which will strengthen collaborative partnerships between Randox, Queen’s University Belfast and Ulster University, will accelerate the development of new technologies and drive healthcare improvements regionally, nationally and across the globe.
Of the £23m of support offered by Invest NI, £5m will go toward research projects at Ulster University and Queen’s University Belfast.
Welcoming the investment, Alastair Hamilton, Chief Executive of Invest NI said;
“Randox has a long history of investing heavily in innovation and R&D which has enabled it to create a globally competitive export driven business, capable of developing world leading research. This major investment will enable Randox to perform cutting-edge R&D which has the potential to revolutionise the global healthcare industry. This is excellent news for Northern Ireland’s life and health sciences sector. Northern Ireland is enjoying a growing international reputation as a region of expertise and knowledge in key areas such as Diagnostics, Precision Medicine and Advanced Manufacturing. The three new Centres of Excellence will help build on this and enhance Northern Ireland’s credibility, provide supply chain opportunities, and encourage knowledge transfer with our universities.”
Sir John Bell, commenting on the potential for the UK Life Sciences sector said;
“The life sciences industry represents one of the dominant economic sectors in the UK, and one with considerable potential for growth. However, whilst we have many natural strengths we cannot afford to be complacent. We must strive to optimise our science base, to encourage collaboration across academia, industry and the NHS, and grow our industrial capabilities. To do so we need to use our extensive data sets to best effect, and have in place a strong skills strategy. Success requires vision and drive. To that end I would like to congratulate Dr FitzGerald and Randox in the establishment of these three R&D collaborative Centres of Excellence – these are assets of national standing and will have a meaningful impact in enabling earlier and more accurate diagnosis, driving improvements in patient care, regionally, nationally and globally. They are leaders in this field, committed to innovation, and I wish them every success.”
Professor Jim McLaughlin, Director of Ulster University’s Nanotechnology and Integrated Bioengineering Centre, added;
“This very welcome investment enables pioneering Randox-inspired engineering capacity at Ulster University and reflects our research commitment to the life sciences industry. From nanotechnology to the development of systems that will enable large scale laboratory capability to be produced in the palm of your hand, the partnership brings shared industry and academic research excellence from the lab into the marketplace. Life sciences is a vital economic sector locally and this collaboration will advance diagnostics and ultimately enhance patient health outcomes.”
Dr David Jess, Senior Lecturer at Queen’s University Belfast School of Mathematics and Physics, added;
“The Randox Centres of Excellence will allow Queen’s University Belfast to continue to deliver cutting-edge and world leading research. We look forward to collaborating further with industry to develop pioneering research, focused on the needs of society.”
Invest NI’s R&D support is part funded by ERDF under the EU Investment for Growth and Jobs Programme 2014 – 2020.
For further information please contact the Randox PR Team: phone 028 9442 2413 or email randoxpr@randox.com
Take control of your heart health with Randox
Your heart is amazing. Not only is it your most critical organ but also one of the most hard-working. The average adult heart beats around 100,000 times a day, acting as a giant pump for all the blood in your body. Indeed, every day your heart pumps over nine litres of blood through a system of blood vessels over 60,000 miles long – it’s little wonder, then, the importance placed on looking after such a vital muscle.
The heart works 24/7, only taking a rest when you sleep with the natural drop of heart rate and blood pressure. Over time, and influenced by lifestyle choices, the heart grows weaker, needing to work harder to fulfil its function. Crucial lifestyle changes now could limit your risk of developing serious cardiac conditions, such as Cardiovascular Disease (CVD) in the future. Factors which can contribute to your CVD risk include genes inherited from parents or grandparents, smoking, an unhealthy diet, excessive alcohol consumption and low physical activity levels.
You can’t change your DNA, but you can find out what it means to you and your family. One of our advanced tests can identify people living with a common but often hidden disorder – Familial Hypercholesterolemia (FH). Fewer than 12% of people in the UK know they have this potentially fatal condition. It is characterised by dangerously high levels of cholesterol which can lead to early onset cardiovascular disease.
While lifestyle changes may help to limit your risk of CVD, and related heart condition, it is impossible to eradicate it completely for everyone. Accounting for 31% of deaths worldwide, CVD is the number one cause of death globally but early screening could lower this figure significantly. That’s why it’s vitally important to detect CVD early before a coronary event like a heart attack occurs.
Today in the UK, 530 people will go to the hospital with a suspected heart attack. Only a fifth of these people will actually be having a heart attack. According to a team from King’s College London, as reported by the BBC, a faster, more accurate diagnosis of whether chest pain is caused by a heart attack would save the health service millions of pounds each year by sending well patients home and freeing up beds. Yet current testing methods do not efficiently differentiate between high-risk patients and the estimated 80% of patients who are not having a heart attack.
Randox’s revolutionary test for Heart-Type Fatty Acid-Binding Protein (H-FABP), when combined with current testing, is able to rule out a heart attack for patients who present at A&E with chest pain which is caused by other conditions such as respiratory issues, meaning they may not need emergency admission.
When measured at the time a patient presents to A&E with chest pain, H-FABP enables doctors to triage patients suffering with a heart attack more efficiently than before, making sure those at high-risk are given medical intervention earlier.
Early screening in the form of a comprehensive health check is essential to detect cardiac irregularities before they become serious problems. Heart damage builds up over time, meaning that when detected early enough, lifestyle changes can help to reduce cardiac risk and potentially even prevent a cardiac event occurring.
Therefore, it is vitally important that individuals are tested for CVD to detect them in the earliest stages to reduce damage, prevent further damage, or even death. Furthermore, many people suffer from inherited cardiac risk factors, which stresses the need for accurate testing.
Randox offer the complete laboratory solution to cardiac risk assessment information to doctors and hospitals, and also directly to the public at Randox Health. Our range of both traditional and novel cardiac risk biomarkers, along with our technologically-advanced range of analysers, serves to allow us to offer the most advanced, most accurate health check available on the planet.
As well as your cardiovascular risk score, a Randox Health check will also assess your cholesterol levels, FH risk, triglycerides, creative kinase, myoglobin, troponin levels and many more heart health indicators. In total, a Randox Health check can assess up to 350 different markers of irregularity or disease in the whole body, from heart to hormone health and skin to stomach.
Many serious future health issues are preventable now with action. Find out more about our health check programmes here.
About Randox Health
Randox Health is a global leader in healthcare diagnostics; today more than 5% of the world’s population – in excess of 370 million people across 145 countries – receives medical diagnosis using Randox products each year.
After investing over £220 million in the invention and production of revolutionary blood-science technology, a single Randox Health check will deliver a complete picture of your health – as it is now and, crucially, how it is likely to develop in the future.
Randox Health has proven that signs of disease or irregularity can be caught at their earliest stage. This means that, with early action, some cases of illness can even be prevented altogether. Our health checks include, but are not limited to, cancer surveillance, fertility monitoring, heart health, nutrition, digestive and diabetes health.
In other words, from one health check, you’ll receive up to 350 results and afterwards avail of expert advice from the Randox scientists or a Randox Health GP. Not only that, but a complete 12-month programme and repeat testing come as standard so you can have full confidence that you are really taking care of yourself.
Find out more information about Randox Health checks here: https://www.randoxhealth.com/our-packages/
RX Series
Randox has developed the RX series range of clinical chemistry analysers for high-quality semi-automated and fully automated testing. Choose between the RX misano, RX monaco, RX daytona+, RX imola, and the RX modena depending on the throughput of your laboratory. The RX series offers a suitable analyser for your laboratory’s needs. For more information on the Randox RX series, please click here or email therxseries@randox.com
Reagents
Randox offers an extensive range of third party diagnostic reagents which are internationally recognised as being of the highest quality; producing accurate and precise results. We have the largest test menu of 118 assays, covering over 100 disease markers including specific proteins, lipids, therapeutic drug monitoring, drugs of abuse, antioxidants, coagulation, diabetes and veterinary testing. A wide range of formats and methods are available providing greater flexibility and choice for any laboratory size. In addition to flexible pack sizes and a comprehensive list of analyser applications, we can also provide dedicated reagent packs (Randox Easy Read and Easy Fit regents) for a wide range of chemistry analysers providing you with freedom of choice from an independent manufacturer.
For more information on Randox Reagents, please click here or email reagents@randox.com
Acusera – Internal Quality Control
The Acusera cardiac controls have been designed to cover a wide range of cardiac markers at clinical decision levels, eliminating the extra expense of an additional low level control. The controls are available in a both liquid ready-to-use and lyophilized formats making them ideal for all situations and manufactured from 100% human serum a matrix similar to that of the patient is guaranteed. For more information on the Randox Acusera internal quality control, please click here or email acusera@randox.com
RIQAS – External Quality Control
The RIQAS Liquid Cardiac EQA programme is designed to monitor the performance of up to 9clinically significant cardiac markers including: CK-MB mass, D-dimer, Digoxin, homocysteine, hsCRP, myoglobin, NT proBNP, troponin I, and troponin T. RIQAS is ISO/IEC 17043 accredited and allows the registration of up to five instruments at no extra cost. All samples are 100% human serum and provided in a liquid ready-to-use format for enhanced convenience. Submit your results bi-weekly and view reports online via RIQAS.Net. For more information on RIQAS, the world’s largest international EQA scheme, please click here or email acusera@randox.com
For further information, please contact the Randox PR team via email: randoxpr@randox.com or phone 028 9442 2413
